Evolving COVID-19 Landscape: Assessing the Effectiveness and Safety Profile of Nirmatrelvir/Ritonavir in Adolescents
PharmD Philip Lee, Kiriam Escobar Lee, MD, MPH Brenda I Anosike
Pediatric Infectious Disease Journal, doi:10.1097/inf.0000000000004594
This study evaluates nirmatrelvir/ritonavir (Paxlovid) in preventing severe coronavirus disease 2019 in adolescents (12-18). Conducted from January 2022 to July 2023, it compared hospital admissions and healthcare visits within 30 days post-treatment. Results showed similar follow-up rates between treated and untreated groups, with slightly more adverse effects in the nirmatrelvir/ritonavir group. Further research is needed to confirm its efficacy in this population.
References
Bahl, Mielke, Johnson, Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing Alpha, Delta, and Omicron variants, Lancet Reg Health Am
Bose-Brill, Hirabayashi, Pajor, Pediatric nirmatrelvir/ritonavir prescribing patterns during the COVID-19 pandemic, medRxiv
Brown, Moore, Hooper, Interventions for preventing obesity in children, Cochrane Database Syst Rev
Choi, Choi, Yun, Risk factors for severe COVID-19 in children: a systematic review and meta-analysis, J Korean Med Sci
Costagliola, Spada, Consolini, Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19, Immun Inflamm Dis
Esposito, Autore, Argentiero, Update on COVID-19 therapy in pediatric age, Pharmaceuticals
Fernandez, Perez, Hernandez, Factors and mechanisms for pharmacokinetic differences between pediatric population and adults, Pharmaceutics
Graff, Smith, Silveira, Risk factors for severe COVID-19 in children, Pediatr Infect Dis J
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for highrisk, nonhospitalized adults with Covid-19, N Engl J Med
Hoering, Leblanc, Crowley, Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents, Clin Cancer Res
Iuliano, Brunkard, Boehmer, Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods-United States, December 2020-January 2022, MMWR Morb Mortal Wkly Rep
Jabakhanji, Boland, Ward, Body mass index changes in early childhood, J Pediatr
Levin, Whittaker, Balancing risk and benefit of SARS-CoV-2 vaccines in children, Lancet Reg Health Eur
Lu, Rosenbaum, Developmental pharmacokinetics in pediatric populations, J Pediatr Pharmacol Ther
Rotulo, Palma, Understanding COVID-19 in children: immune determinants and post-infection conditions, Pediatr Res
Saravolatz, Depcinski, Sharma, Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs, Clin Infect Dis
Taylor, Whitaker, Anglin, COVID-19-associated hospitalizations among adults during SARS-CoV-2 delta and omicron variant predominance, by race/ethnicity and vaccination status-COVID-NET, 14 states, July 2021, Morb Mortal Wkly Rep
Woodruff, Campbell, Taylor, Risk factors for severe COVID-19 in children, Pediatrics
Yaffe, Pharmacokinetics and pharmacodynamics in children versus adults
Yan, Zhou, Zhu, The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study, Ann Transl Med
DOI record:
{
"DOI": "10.1097/inf.0000000000004594",
"ISSN": [
"0891-3668",
"1532-0987"
],
"URL": "http://dx.doi.org/10.1097/INF.0000000000004594",
"abstract": "<jats:p>This study evaluates nirmatrelvir/ritonavir (Paxlovid) in preventing severe coronavirus disease 2019 in adolescents (12–18). Conducted from January 2022 to July 2023, it compared hospital admissions and healthcare visits within 30 days post-treatment. Results showed similar follow-up rates between treated and untreated groups, with slightly more adverse effects in the nirmatrelvir/ritonavir group. Further research is needed to confirm its efficacy in this population.</jats:p>",
"author": [
{
"ORCID": "http://orcid.org/0000-0002-5039-3522",
"affiliation": [
{
"name": "Albert Einstein College of Medicine, Bronx, New York"
},
{
"name": "Division of Pediatric Infectious Disease, Children’s Hospital at Montefiore, Bronx, New York"
},
{
"name": "Department of Pharmacy, Montefiore Medical Center, Bronx, New York."
}
],
"authenticated-orcid": false,
"family": "Lee",
"given": "Philip",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Albert Einstein College of Medicine, Bronx, New York"
},
{
"name": "Division of Pediatric Infectious Disease, Children’s Hospital at Montefiore, Bronx, New York"
}
],
"family": "Lee",
"given": "Kiriam Escobar",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Albert Einstein College of Medicine, Bronx, New York"
},
{
"name": "Division of Pediatric Infectious Disease, Children’s Hospital at Montefiore, Bronx, New York"
}
],
"family": "Anosike",
"given": "Brenda I.",
"sequence": "additional"
}
],
"container-title": "Pediatric Infectious Disease Journal",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"lww.com",
"ovid.com"
]
},
"created": {
"date-parts": [
[
2024,
11,
14
]
],
"date-time": "2024-11-14T15:02:14Z",
"timestamp": 1731596534000
},
"deposited": {
"date-parts": [
[
2024,
11,
14
]
],
"date-time": "2024-11-14T15:02:21Z",
"timestamp": 1731596541000
},
"indexed": {
"date-parts": [
[
2024,
11,
14
]
],
"date-time": "2024-11-14T15:40:10Z",
"timestamp": 1731598810848,
"version": "3.28.0"
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2024,
11,
14
]
]
},
"language": "en",
"link": [
{
"URL": "https://journals.lww.com/10.1097/INF.0000000000004594",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "276",
"original-title": [],
"prefix": "10.1097",
"published": {
"date-parts": [
[
2024,
11,
14
]
]
},
"published-online": {
"date-parts": [
[
2024,
11,
14
]
]
},
"publisher": "Ovid Technologies (Wolters Kluwer Health)",
"reference": [
{
"DOI": "10.1093/cid/ciac180",
"article-title": "Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs.",
"author": "Saravolatz",
"doi-asserted-by": "crossref",
"first-page": "165",
"journal-title": "Clin Infect Dis",
"key": "R3-20241114",
"volume": "76",
"year": "2023"
},
{
"article-title": "Interventions for preventing obesity in children.",
"author": "Brown",
"first-page": "1",
"journal-title": "Cochrane Database Syst Rev",
"key": "R5-20241114",
"volume": "2019",
"year": "1996"
},
{
"DOI": "10.1016/j.jpeds.2018.06.049",
"article-title": "Body mass index changes in early childhood.",
"author": "Jabakhanji",
"doi-asserted-by": "crossref",
"first-page": "106",
"journal-title": "J Pediatr",
"key": "R6-20241114",
"volume": "202",
"year": "2018"
},
{
"article-title": "Pediatric nirmatrelvir/ritonavir prescribing patterns during the COVID-19 pandemic.",
"author": "Bose-Brill",
"first-page": "2022.12.23.222838682022",
"journal-title": "medRxiv [Preprint]",
"key": "R7-20241114",
"year": "2022"
},
{
"DOI": "10.1056/NEJMoa2118542",
"article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.",
"author": "Hammond",
"doi-asserted-by": "crossref",
"first-page": "1397",
"journal-title": "N Engl J Med",
"key": "R8-20241114",
"volume": "386",
"year": "2022"
},
{
"article-title": "Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing Alpha, Delta, and Omicron variants.",
"author": "Bahl",
"first-page": "100405",
"journal-title": "Lancet Reg Health Am",
"key": "R9-20241114",
"volume": "18",
"year": "2023"
},
{
"DOI": "10.15585/mmwr.mm7112e2",
"article-title": "COVID-19–associated hospitalizations among adults during SARS-CoV-2 delta and omicron variant predominance, by race/ethnicity and vaccination status—COVID-NET, 14 states, July 2021–January 2022.",
"author": "Taylor",
"doi-asserted-by": "crossref",
"first-page": "466",
"journal-title": "Morb Mortal Wkly Rep",
"key": "R10-20241114",
"volume": "71",
"year": "2022"
},
{
"DOI": "10.15585/mmwr.mm7104e4",
"article-title": "Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020–January 2022.",
"author": "Iuliano",
"doi-asserted-by": "crossref",
"first-page": "146",
"journal-title": "MMWR Morb Mortal Wkly Rep",
"key": "R11-20241114",
"volume": "71",
"year": "2022"
},
{
"DOI": "10.1158/1078-0432.CCR-10-1262",
"article-title": "Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.",
"author": "Hoering",
"doi-asserted-by": "crossref",
"first-page": "640",
"journal-title": "Clin Cancer Res",
"key": "R12-20241114",
"volume": "17",
"year": "2011"
},
{
"DOI": "10.3390/pharmaceutics3010053",
"article-title": "Factors and mechanisms for pharmacokinetic differences between pediatric population and adults.",
"author": "Fernandez",
"doi-asserted-by": "crossref",
"first-page": "53",
"journal-title": "Pharmaceutics",
"key": "R13-20241114",
"volume": "3",
"year": "2011"
},
{
"article-title": "Developmental pharmacokinetics in pediatric populations.",
"author": "Lu",
"first-page": "262",
"journal-title": "J Pediatr Pharmacol Ther",
"key": "R14-20241114",
"volume": "19",
"year": "2014"
},
{
"DOI": "10.1038/s41390-023-02549-7",
"article-title": "Understanding COVID-19 in children: immune determinants and post-infection conditions.",
"author": "Rotulo",
"doi-asserted-by": "crossref",
"first-page": "434",
"journal-title": "Pediatr Res",
"key": "R16-20241114",
"volume": "94",
"year": "2023"
},
{
"DOI": "10.1002/iid3.404",
"article-title": "Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.",
"author": "Costagliola",
"doi-asserted-by": "crossref",
"first-page": "331",
"journal-title": "Immun Inflamm Dis",
"key": "R17-20241114",
"volume": "9",
"year": "2021"
},
{
"DOI": "10.1016/j.lanepe.2022.100412",
"article-title": "Balancing risk and benefit of SARS-CoV-2 vaccines in children.",
"author": "Levin",
"doi-asserted-by": "crossref",
"first-page": "100412",
"journal-title": "Lancet Reg Health Eur",
"key": "R18-20241114",
"volume": "18",
"year": "2022"
},
{
"article-title": "Risk factors for severe COVID-19 in children: a systematic review and meta-analysis.",
"author": "Choi",
"first-page": "1",
"journal-title": "J Korean Med Sci",
"key": "R19-20241114",
"volume": "37",
"year": "2022"
},
{
"DOI": "10.1097/INF.0000000000003043",
"article-title": "Risk factors for severe COVID-19 in children.",
"author": "Graff",
"doi-asserted-by": "crossref",
"first-page": "e137",
"journal-title": "Pediatr Infect Dis J",
"key": "R20-20241114",
"volume": "40",
"year": "2021"
},
{
"DOI": "10.1542/peds.2021-053418",
"article-title": "Risk factors for severe COVID-19 in children.",
"author": "Woodruff",
"doi-asserted-by": "crossref",
"first-page": "e2021053418",
"journal-title": "Pediatrics",
"key": "R21-20241114",
"volume": "149",
"year": "2022"
},
{
"DOI": "10.3390/ph15121512",
"article-title": "Update on COVID-19 therapy in pediatric age.",
"author": "Esposito",
"doi-asserted-by": "crossref",
"first-page": "1512",
"journal-title": "Pharmaceuticals",
"key": "R22-20241114",
"volume": "15",
"year": "2022"
},
{
"DOI": "10.21037/atm-22-2791",
"article-title": "The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study.",
"author": "Yan",
"doi-asserted-by": "crossref",
"first-page": "619",
"journal-title": "Ann Transl Med",
"key": "R23-20241114",
"volume": "10",
"year": "2022"
}
],
"reference-count": 19,
"references-count": 19,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.lww.com/10.1097/INF.0000000000004594"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Evolving COVID-19 Landscape: Assessing the Effectiveness and Safety Profile of Nirmatrelvir/Ritonavir in Adolescents",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1097/lww.0000000000001000"
}
